SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA bans Dr Reddy's Mexico plant’s drugs

07 Jul 2011 Evaluate

Dr Reddy's Laboratories' Indian drug maker received a warning letter from the US Food and Drug Administration (FDA) to its Mexican facility for violating manufacturing standards. FDA has imposed an import ban on products made at this unit of the company. FDA warned the company that failure to correct these violations may see the regulator refuse entry into the United States, a key export market for the firm, of products manufactured at Dr Reddy's Mexican facility.

Recently Dr Reddy’s Laboratories has launched Levofloxacin tablets 250mg, 500mg, and 750mg, a bioequivalent generic version of Levaquin tablets in the US market on June 20, 2011, following the approval by the United States Food and Drug Administration (USFDA) of the company’s Abbreviated New Drug Application (ANDA) for Levofloxacin tablets.

The company’s net profit for the fourth quarter declined by 34.48% at Rs 165.87 crore as compared to Rs 253.16 crore for the corresponding quarter previous year. Its total income increased by 7.11% at Rs 1375.77 crore for the quarter under review from Rs 1284.43 crore in the corresponding previous quarter.

Dr. Reddys Lab Share Price

1291.05 19.50 (1.53%)
22-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1863.45
Dr. Reddys Lab 1291.05
Cipla 1415.30
Zydus Lifesciences 1084.35
Lupin 2339.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: